Ceryvyn Therapeutics Ltd. - Unsponsored ADR
CYVNY Healthcare Biotechnology
Ceryvyn Therapeutics Ltd. - Unsponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $25,000.00, down 80.0% from fiscal 2024.
Follow CYVNY
Ceryvyn Therapeutics Ltd. - Unsponsored ADR (CYVNY) EV/Sales
As of 15 October 2026, Ceryvyn Therapeutics Ltd. - Unsponsored ADR (CYVNY) trades at a EV/Sales of 759×. Over the past ten years it has ranged from 0.0× (December 2022) to 1,162× (November 2025); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1,162× | 233.98% |
| FY2024 | 348× | 9.41% |
| FY2023 | 318× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 780× | (26.41%) |
| Dec 2022 | 1,060× | — |
| Dec 2021 | 0.0× | — |
| Dec 2020 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FTH Faeth Therapeutics, Inc. compare | n/m |
| VECT VectivBio Holding AG compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 1.9× |
| VALN Valneva SE Sponsored ADR compare | 3.5× |
| CTMX CytomX Therapeutics, Inc. compare | 9.3× |
| ACRS Aclaris Therapeutics, Inc. compare | 47.1× |
| STTK Shattuck Labs, Inc. compare | 88.3× |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR | 759× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)